Results 21 to 30 of about 2,721,081 (186)

Genetic Polymorphisms Associated with Valproic Acid Therapy: Review article

open access: yesSVU - International Journal of Medical Sciences, 2022
Background: Valproic acid is an important anticonvulsant and mood-stabilizing drug. It is also used in the therapy of bipolar disorders, migraine, cancer and neurodegenerative disorders.
Reham A.M. Ellisy*   +4 more
doaj   +1 more source

Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia

open access: yesScientific Reports, 2021
Valproic acid is an anticonvulsant, which is also widely used for treating psychiatric disorders. Some clinical trials have demonstrated benefits of valproic acid augmentation therapy in schizophrenia.
S. Wang   +7 more
doaj   +1 more source

Association of ABCB1 Polymorphisms with Efficacy and Adverse Drug Reactions of Valproic Acid in Children with Epilepsy

open access: yesPharmaceuticals, 2023
Genetic polymorphisms in ATP-binding cassette subfamily B member 1 (ABCB1, also known as MDR1) have been reported to be possibly associated with the regulation of response to antiseizure medications.
Jiahao Zhu   +7 more
doaj   +1 more source

Valproic acid-induced hyperammonemic encephalopathy: a clinical case

open access: yesEuropean Psychiatry, 2022
Introduction Valproic acid is a psychotropic drug used for several years, due to its properties as a mood stabilizer, being considered as first-line treatment for bipolar disorder.
M. Felizardo, C. Freitas
doaj   +1 more source

Antioxidative effect of metformin on valproic acid induced hepatoxicity in male rats

open access: yesAl-Mustansiriyah Journal of Pharmaceutical Sciences, 2022
Metformin is 1,1-dimethylbiguanide hydrochloride, is the first-line therapy for type 2 diabetes. Additionally, several studies focused on the role of metformin in antioxidant activities for the treatment of hepatic disorders. The experimentally    
Intesar Tarik Numan   +2 more
doaj   +1 more source

Serum concentrations of valproic acid in people with epilepsy: Clinical implication [PDF]

open access: yesJournal of Pharmacy & Pharmacognosy Research, 2022
Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions.
Angel T. Alvarado   +12 more
doaj   +1 more source

Chard extract increased gastric sialic acid and ameliorated oxidative stress in valproic acid-administered rats [PDF]

open access: yes, 2023
Valproic acid, one of the most used drugs for epilepsy patients, has some known side effects. Chard extract has many pharmacological activities. The study aims to evaluate whether valproic acid might interfere with oxidative metabolism in gastric tissue ...
Tunalı, Sevim   +7 more
core   +3 more sources

VALPROIC ACID TOXICITY INDUCED BY LACOSAMIDE: A RARE CASE REPORT [PDF]

open access: yes, 2017
Valproic acid is commonly used in the treatment of both focal and generalized epilepsies and is often tolerated well.Valproic acid is usually tolerated well, but serious complications, including hepatotoxicity and hyperammonemic encephalopathy, may occur.
Chandran, Chanshi   +2 more
core   +3 more sources

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo [PDF]

open access: yes, 2008
Histone deacetylase (HDAC) inhibitors represent a promising class of antineoplastic agents which affect tumour growth, differentiation and invasion. The effects of the HDAC inhibitor valproic acid (VPA) were tested in vitro and in vivo on pre-clinical ...
Eva Juengel   +13 more
core   +1 more source

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]

open access: yes, 2013
Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Eva Juengel   +20 more
core   +2 more sources

Home - About - Disclaimer - Privacy